



[Journal List](#) > [Blood](#)

Blood. 2009 March 5; 113(10): 2217–2228.

PMCID: PMC2673991

Prepublished online 2008 December 23. doi: 10.1182/blood-2008-03-144840.

[Copyright](#) © 2009 by The American Society of Hematology

Immunobiology

Indian hedgehog (Ihh) both promotes and restricts thymocyte differentiation

Susan V. Outram,^{1*} Ariadne L. Hager-Theodorides,^{1*} Divya K. Shah,^{1*} Nicola J. Rowbotham,¹ Ekati Drakopoulou,¹ Susan E. Ross,¹ Beate Lanske,² Johannes T. Dessens,³ and Tessa Crompton^{✉1}

¹Immunobiology Unit, University College London Institute of Child Health, London, United Kingdom;

²Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA; and

³Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

✉Corresponding author.

*S.V.O., A.L.H.-T., and D.K.S. contributed equally to this study.

Received March 12, 2008; Accepted November 16, 2008.

▶ This article has been [cited by](#) other articles in PMC.

Abstract

We show that Indian Hedgehog (Ihh) regulates T-cell development and homeostasis in both fetal and adult thymus, controlling thymocyte number. Fetal *Ihh*^{-/-} thymi had reduced differentiation to double-positive (DP) cell and reduced cell numbers compared with wild-type littermates. Surprisingly, fetal *Ihh*^{+/-} thymi had increased thymocyte numbers and proportion of DP cells relative to wild type, indicating that *Ihh* also negatively regulates thymocyte development. In vitro treatment of thymus explants with exogenous recombinant Hedgehog protein promoted thymocyte development in *Ihh*^{-/-} thymi but inhibited thymocyte development in *Ihh*^{+/-}, confirming both positive and negative regulatory functions of *Ihh*. Analysis of *Rag*^{-/-}*Ihh*^{+/-} thymi showed that *Ihh* promotes T-cell development before pre-T-cell receptor (pre-TCR) signaling, but negatively regulates T-cell development only after pre-TCR signaling has taken place. We show that *Ihh* is most highly

expressed by the DP population and that Ihh produced by DP cells feeds back to negatively regulate the differentiation and proliferation of their double-negative progenitors. Thus, differentiation from double-negative to DP cell, and hence the size of the DP population, is dependent on the concentration of Ihh in the thymus. Analysis of Ihh conditional knockout and heterozygote adult mice showed that Ihh also influences thymocyte number in the adult.

Introduction

Here we show that the intercellular signaling molecule, Indian Hedgehog (Ihh), regulates T-cell development, thereby restricting thymocyte number

Thymus size is tightly controlled by processes intrinsic to the thymus, about which little is known. The control of thymocyte number has been assumed to rely on competition between thymocyte precursors for limiting concentrations of mitogenic or survival factors, that by positively regulating the fate of the progenitor cell population control the number of thymocytes produced. Many factors have been described that promote the expansion of thymocyte progenitors and promote T-cell development, including cytokines,¹ Notch signaling,^{2,3} the Wnt protein family,⁴ and Sonic Hh (Shh).⁵ Little, however, is understood about mechanisms that provide feedback, or a counting system, negatively regulating the upper limits of thymocyte differentiation and number. Here we show that Ihh provides such a counting system, negatively regulating the rate of differentiation from CD4⁻CD8⁻ double-negative (DN) to CD4⁺CD8⁺ double-positive (DP) cell, and hence T-cell production and thymus size.

The Hh protein family (Shh, Ihh, and Desert Hh [Dhh]) signals for development, patterning, and organogenesis of many tissues during mammalian embryogenesis^{6,7} and is also involved in homeostasis and renewal of adult tissues, including blood and thymus.⁸⁻¹¹ They can act as classic morphogens, giving concentration-dependent signals for position and patterning, and can regulate cell survival and proliferation.^{6,7} The 3 Hh proteins have distinct temporal and tissue-specific expression patterns and functions.^{12,13} Although Shh and Ihh are each essential during embryogenesis and have some overlapping functions,¹⁴ Shh is more pleiotropic and nonredundant in its actions, whereas Ihh has specialized functions in bone, cartilage, and gut.¹³⁻¹⁵ The Hh proteins share a common signaling pathway.

They bind to the receptor Patched (Ptc), which releases the signal transduction protein Smoothed (Smo) to transmit a signal into the cell. In the absence of Hh, Ptc inhibits the activity of Smo. The downstream components of the signaling pathway are the glioblastoma-associated protein (Gli) family of transcription factors: Gli1, Gli2, and Gli3.^{7,16}

During $\alpha\beta$ T-cell development, CD4⁻CD8⁻ DN cells give rise to the CD4⁺CD8⁺ DP population, which differentiate to mature CD8⁺CD4⁻ or CD8⁻CD4⁺ single-positive (SP) cells. The DN population can be further subdivided by cell-surface expression of CD25 and CD44. CD44⁺CD25⁻ (DN1) cells differentiate to become CD44⁺CD25⁺ (DN2) cells, which then differentiate to become CD44⁻CD25⁺ (DN3). The DN3 population gives rise to the CD44⁻CD25⁻ (DN4) subset, which undergo a phase of rapid proliferation before differentiation into the DP population, in general via a cycling immature CD8⁺ intermediate single-positive (ISP) cell. T-cell lineage specification and T-cell receptor- β (TCR- β) chain rearrangements occur in the CD25⁺ (DN2 and DN3) population. Pre-TCR signaling is necessary for differentiation to DP cell,¹⁷ but other largely unidentified signals dependent on normal thymus architecture and cellular composition are also required.¹⁸

Shh, Ihh, and components of the Hh signaling pathway are expressed in the mouse thymus.^{10,19-23} In vitro studies first demonstrated that Hh signaling influences thymocyte development,^{10,24} and although they did not determine which Hh protein (Shh or Ihh) was physiologically significant, suggested that Hh signaling was predominantly a negative regulator of T-cell development. In contrast, subsequent ex vivo analysis of Shh^{-/-} thymi revealed multiple positive-regulatory functions for Shh during fetal T-cell development. Absence of Shh caused reductions in thymocyte number, DN cell proliferation, differentiation from DN1 to DN2 cell, survival of DN4 cells, production of DP cells,⁵ and the ratio of mature CD8/CD4 SP cells.^{22,25,26} Conditional deletion of Smo from T-lineage cells has also shown that the Hh pathway provides essential positive signals for homeostasis of the earliest DN subsets and for differentiation from DN1 to DN2 but did not reveal any influence of Hh signaling on T-cell development after the DN2 stage.²¹

Here we take a genetic approach to assess the function of Ihh during thymocyte development, thereby reconciling conflicting data from earlier experimental systems.^{5,10,21,23,24} We demonstrate, by analysis of null and

conditional-null mutants, that Ihh, produced by thymocytes themselves, regulates T-cell development and homeostasis in fetal and adult thymus. We show that Ihh and Shh have distinct but overlapping functions in the thymus, and that whereas Shh, secreted by the epithelium, is dominant in positively signaling for proliferation and differentiation of early DN progenitors, Ihh, produced by thymocytes, functions to control thymocyte numbers by negatively regulating the transition from icTCR- β + DN3 to DP, providing concentration-dependent feedback on the production of DP cells.

Methods

Mice

C57BL/6 mice (B&K Universal, Hull, United Kingdom), Shh^{+/-12} and Ihh^{+/-13} mice, gifts from Philip Beachy (The Johns Hopkins University School of Medicine, Baltimore, MD) and Andrew McMahon (Harvard University, Cambridge, MA), respectively, were backcrossed onto C57BL/6 mice for more than 11 generations. Cre transgenic mice,²⁷ a gift from Dimitris Kioussis (The National Institute for Medical Research, London, United Kingdom), and Floxed Ihh mice,¹⁵ were bred and maintained at Imperial or University College London, under United Kingdom Home Office regulations. Timed mates were as described.⁵ All animal experiments were approved by the institutional review board of University College London (London, United Kingdom).

Fetal thymus organ cultures

Fetal thymus organ cultures (FTOCs) were as described.⁵ Where stated, FTOCs were treated with recombinant mouse Sonic Hedgehog N-Terminus protein (catalog number 464-SH; R&D Systems, Minneapolis, MN) or 1 μ g/mL azide-free anti-CD3 (BD Biosciences PharMingen, San Diego, CA).

Flow cytometry and antibodies

Thymi were dissected, and cell suspensions were prepared, stained, and analyzed as described,^{5,28} using directly conjugated antibodies from BD Biosciences PharMingen. Data are representative of more than 3 experiments. Statistical analysis was the unpaired Student *t* test (equal or

unequal variance depending on data) and the F test. To allow comparison between litters, the number of cells recovered from each thymus, or the percentage of cells staining positive with a given antibody, were divided by the mean value from wild-type (WT) thymi from the same litter, to give a relative value or relative cell number. At least 3 different litters of any embryonic day (E) were analyzed.

Genotyping and PCR analysis

$Ihh^{-/-}$ embryos die around birth, and from E16.5 can be identified phenotypically by their shortened limbs and slightly small size, whereas $Ihh^{+/-}$ embryos and adults are healthy and phenotypically indistinguishable from WT.¹³ In addition to phenotypic identification, all embryos and animals were genotyped by polymerase chain reaction (PCR).

DNA extraction and PCR analysis were as described,⁵ using approximately 0.5 μ g genomic DNA as template, on a Stratagene Robocycler (Stratagene, La Jolla, CA). Primers: *Ihh*/neo, forward: AGGAGGCAGGGACATGGATAGGGTG, reverse: TACCGGTGGATGTGGAATGTGTGCG. *Shh*/neo, forward: CTGTGCTCGACGTTGTA CTG, reverse: AAGCCCG-AGACTTGTGTGGA.

Cre, forward: AGATGCCAGGACATCAGGAACCTG, reverse: TACCGGTGGATGTGGAATGTGTGCG; *Ihh* WT and *Ihh* fl/fl as described.¹³

Real-time RT-PCR

RNA extraction and cDNA synthesis were as described.²³ One primer for each pair was designed to span exon-exon boundaries to avoid amplification of genomic DNA. Primers: *Ihh*, forward: CGACATCATCTTCAAGGACG, reverse: GTCACCCGCAGTTTCACAC; *HPRT* and *Gli1* as described.²²


Quantitative PCR of VDJ TCR- β rearrangement

TCR- β VDJ rearrangement measurement was carried out as described.²⁹

Results

Expression of *Ihh* and *Gli1* in thymus populations

We have described *Ihh* expression in the whole thymus.¹⁰ Here we assess expression of *Ihh* in fluorescence-activated cell sorter (FACS)–sorted E16.5 fetal thymocyte populations and fetal thymus stroma. We found *Ihh* expression in both thymus stroma and thymocytes, with highest expression in the DP population. In the sorted thymocyte populations, low *Ihh* expression, equivalent to that found in the stroma, was detectable in the DN3 population, and relative expression increased 6-fold between the DN3 and DP populations ([Figure 1A](#)).




Both RT-PCR analysis and cell-surface staining have shown that *Smo* expression is highest in the CD25⁺ DN population, and down-regulated in the subsequent DN4 and DP populations, indicating that the DP cells are probably unable to respond to an Hh signal,^{10,21} and DP cells are not responsive to *Shh* treatment in vitro.¹⁰ The transcription factor *Gli1* is a ubiquitous transcriptional target of Hh signaling but is not necessary to initiate the Hh signal, and measurement of its transcription is used as a readout of Hh signaling in a cell population.³⁰ Therefore, to determine which fetal thymocyte populations responded to the Hh signal ex vivo, we assessed *Gli1* transcription in sorted fetal thymocyte populations. As predicted by the pattern of *Smo* expression, we found highest *Gli1* transcription in the CD25⁺ DN populations (DN2 and DN3), and *Gli1* transcription was down-regulated in the subsequent DN4 and DP populations ([Figure 1B](#)). This pattern of expression correlates well with the expression of *Gli3* and *Gli2* in thymocytes, which are both expressed in DN populations but down-regulated at the DP stage, confirming that DP thymocytes cannot transduce the Hh signal.^{21–23} Thus, the DP population had the highest expression of *Ihh* but did not express significant levels of *Gli1*, implying that they were not themselves responding to an autocrine Hh signal, but rather signaling back to an earlier

cell ([Figure 1A,B](#)).

Ihh has a redundant function at the transition from DN1 to DN2


To assess the function of Ihh during fetal T-cell development, we studied thymocyte development in *Ihh*^{-/-} embryos. Given that *Smo*, *Shh*, and *Gli3* are important for differentiation from DN1 to DN2,^{5,21,23} we investigated a role for *Ihh* at the same developmental checkpoint. We analyzed E13.5 and E14.5 thymi, when the DN1 to DN2 transition first occurs. On E13.5, *Shh*^{-/-} thymi had a reduction in cell number, proportion of CD45⁺ cells, and differentiation from DN1 to DN2.⁵ In contrast, we found no differences in the percentage of CD45⁺ cells or the proportion of DN1 and DN2 populations between *Ihh*^{-/-} and littermate thymi ([Figure 1C,D](#)). We likewise found no differences in cell-surface expression of CD117 and B220 on the CD45⁺CD44⁺ thymocytes between *Ihh*^{-/-} and littermate thymi ([Figure 1E,F](#)). On E14.5, the *Shh*^{-/-} thymus contained approximately one tenth the number of thymocytes of its WT littermates, and the size of each thymus lobe was greatly reduced ([Figure 1Gi](#)). The E14.5 *Ihh*^{-/-} thymi, however, were not obviously smaller than WT littermate thymi ([Figure 1Gii,H](#)). Given that we did not detect an essential function for *Ihh* at this stage of thymopoiesis and *Shh* and *Ihh* have overlapping functions in other tissues,^{6,7,14} we assessed redundancy between these 2 factors. We analyzed early thymocyte development and differentiation from DN1 to DN2 in double mutants. *Shh*^{-/-}*Ihh*^{-/-} double knockout embryos die in utero at E9.5,¹⁴ so we analyzed E13.5 *Shh*^{+/-}*Ihh*^{-/-} and littermate thymi. On E13.5, the *Shh*^{+/-} thymus is phenotypically normal. Deletion of one copy of *Shh* in *Ihh*^{-/-} (*Shh*^{+/-}*Ihh*^{-/-}) did not affect the proportion of CD45⁺ cells, but did, however, reduce the proportion of DN2 cells, from 27% in a *Ihh*^{-/-}*Shh*^{+/+} thymus, to 6.9% in the *Ihh*^{-/-}*Shh*^{+/-} thymus ([Figure 2](#)). We found no differences in cell-surface expression of CD117 and B220 on the CD45⁺CD44⁺ DN1 thymocytes between *Ihh*^{-/-}*Shh*^{+/-} and littermate thymi (data not shown).



These data reveal a function for Ihh at the DN1 to DN2 transition and indicate that, in the E13.5 *Ihh*^{-/-} thymus, Shh can compensate for absence of Ihh, but that overall concentration of Hh protein is limiting. As we did not detect *Ihh* transcription in the fetal DN1 and DN2 populations ([Figure 1A](#)), the function of Ihh on E13.5 is probably mediated by Ihh produced by the thymic stroma. Given that the proportion of CD45⁺ cells was not reduced by absence of one copy of *Shh*, we found no evidence that Ihh is involved in the seeding of the thymus or expansion of early progenitor cells. This function seems to be unique to Shh.

Ihh negatively regulates the transition from DN to DP

To determine whether Ihh is important at the transition from DN to DP cell, we compared thymocyte development in E16.5 *Ihh*^{-/-}, *Ihh*^{+/-}, and WT littermates. As E16.5 is the day of embryonic development on which DP cells first appear, the transition from DN to DP on E16.5 is largely synchronized. Thymocyte number was reduced in *Ihh*^{-/-} thymi to less than half of WT littermate thymi, but surprisingly *Ihh*^{+/-} thymi contained on average 1.4 times more thymocytes than WT thymi, and there was greater variation between individual *Ihh*^{+/-} thymi ([Figure 3A](#)). The differences in thymocyte number relative to WT were statistically significant for both *Ihh*^{-/-} and *Ihh*^{+/-} embryos and were reflected in the size of the thymus lobes ([Figure 3B](#)).



In *Ihh*^{-/-} thymi, the proportion of DP cells was reduced ([Figure 3C,D](#)). In *Ihh*^{+/-} thymi, however, both the proportion and absolute number of DP cells were increased, compared with WT, and on average the *Ihh*^{+/-} thymus contained 2.4 times more DP cells than WT thymi ([Figure 3C,D](#)); 6.2% of cells were DP in *Ihh*^{-/-} thymi compared with 10.4% and 17.3% in WT and

Ihh^{+/-} littermate thymi, respectively ([Figure 3D](#)). Given that the increase in production of DP cells in the *Ihh*^{+/-} thymus was surprising, we used quantitative RT-PCR analysis of RNA from embryonic DP thymocytes to confirm expression levels of *Ihh* in WT, *Ihh*^{+/-}, and *Ihh*^{-/-}. As expected, *Ihh* transcription was reduced 2-fold from WT to *Ihh*^{+/-} and was not detectable in *Ihh*^{-/-} ([Figure 3E](#)).


Although the reduction in DP cells in the *Ihh*^{-/-} thymus showed that *Ihh* promotes T-cell development (as seen in E13.5 *Ihh*^{-/-}*Shh*^{+/-} thymi, [Figure 2B](#)), the opposing phenotypes of the ^{-/-} and ^{+/-} mutants indicated that *Ihh* also negatively regulates the transition from DN to DP, as reducing the concentration of *Ihh* to one half of that of the WT thymus increased the production of DP thymocytes by more than 2-fold ([Figure 3C,D](#)).

Ihh is not required for TCR-β locus rearrangement

We found an overall increase in percentage of DN cells but a significant decrease in the proportion of DN4 cells in the *Ihh*^{-/-} thymus ([Figure 3F](#)). Because transition to the DP stage requires pre-TCR signaling, the reduced differentiation from DN3 to DP observed in *Ihh*^{-/-} thymus could be the result of failure to rearrange the TCR-β chain locus. To test this, we assessed the ability of DN3 thymocytes to produce functional TCR-β chain protein by measuring intracellular (ic) TCR-β chain expression. The *Ihh*^{-/-} DN3 population expressed icTCR-β, and the percentage of icTCR-β⁺ cells in the DN3 population was indeed marginally higher in the *Ihh*^{-/-} embryos compared with WT littermates ([Figure 3G,H](#)). We confirmed that TCR-β locus rearrangement was efficient in the *Ihh*^{-/-} thymus, by quantitative PCR²⁹ using 5' primers to Vβ8.2 and Vβ5.1 and a 3' primer to Jβ2.7 ([Figure 3I](#)). We found no evidence for reduction in efficiency of TCR-β locus rearrangement between *Ihh*^{-/-} and WT. Because successful TCR-β locus rearrangement is associated with release from cell-cycle arrest,³¹ we also assessed cell-cycle status by propidium iodide (PI) staining of sorted DN3 cells from WT and *Ihh*^{-/-} littermates. We found no significant difference in the proportion of cells in S + G₂/M ([Figure 3J](#)). We therefore found no evidence for a reduction in TCR-β locus rearrangement.

Ihh is a negative regulator of DN3 cell proliferation

To identify the target cell of Ihh's negative regulation of cell number, we sorted CD25⁺ DN, CD8ISP, and DP populations from E16.5 Ihh^{+/-} and WT thymi and assessed cell-cycle status by PI staining. There was no difference in the percentage of cells in cycle between the DP populations, but the Ihh^{+/-} CD25⁺ DN population contained significantly more cells in S/G₂ plus M than its WT counterpart, identifying it as a target of Ihh's negative regulation of expansion and differentiation ([Figure 4A](#)). In addition, a small but significant increase in the proportion of cells in cycle was observed in the Ihh^{+/-} CD8ISP population, relative to WT ([Figure 4A](#)).



Ihh promotes DN thymocyte development before pre-TCR signal transduction but is a negative regulator after pre-TCR signal transduction

Because Ihh provides both positive and negative regulatory signals for the differentiation and proliferation of DN thymocytes, we asked when in thymocyte development the positive and negative signals occur with respect to pre-TCR signaling. We compared cell number between Ihh^{+/+}Rag^{-/-} and Ihh^{+/-}Rag^{-/-} thymi and found that the Ihh^{+/-}Rag^{-/-} thymi were significantly smaller than those of Ihh^{+/+}Rag^{-/-} littermates ([Figure 4B](#); $P < .001$), demonstrating that Ihh transmits the positive signal before pre-TCR signal transduction. This is consistent with its early function at the transition from DN1 to DN2.

We then tested whether Ihh^{+/-}Rag^{-/-} thymocytes expand more efficiently than their Ihh^{+/+}Rag^{-/-} counterparts after FTOC treatment with anti-CD3, thereby mimicking a signal through the pre-TCR. For each thymus, we treated one lobe with anti-CD3 monoclonal antibody for 5 days and calculated the fold increase in thymocyte number relative to the number of cells in the other untreated lobe from the same thymus. The number of

thymocytes in *Ihh*^{+/-}*Rag*^{-/-} FTOCs increased on average 13 times during the culture period, compared with a 9-fold expansion in the *Ihh*^{+/+}*Rag*^{-/-} FTOCs (Figure 4C). This difference was statistically significant ($P = .03$). Thus, *Ihh* promoted thymocyte development before pre-TCR signaling but negatively regulated thymocyte development after pre-TCR signaling has taken place.

Ihh regulates fetal thymus homeostasis

We have shown that reduced concentration of *Ihh* promotes differentiation from DN3 to DP stage and that the DN3 subset is the target population for this negative regulatory function of *Ihh* (Figures 3, 4). In addition, our expression analysis has shown that thymocytes, and in particular the DP population, provide most of the *Ihh* in the thymus (Figure 1A). Concentration of *Ihh* in the thymus will therefore depend largely on the number of DP thymocytes (ie, *Ihh*-producing cells). Taken together, our data suggest that *Ihh* produced by the thymocytes feeds back to negatively regulate the proliferation and differentiation of DN3 cells after pre-TCR signal transduction, in a concentration-dependent manner. Thus, *Ihh* signaling in the thymus provides a counting system for post-DN3 thymocyte number.

In the heterozygote fetal thymus, the *Ihh*^{+/-} thymocytes make half the concentration of *Ihh* transcript (Figure 3E) compared with that of their WT counterparts; thus, the amount of *Ihh* signaling would be approximately half that observed in the WT thymus. Therefore, given this reduced negative regulatory signal in the *Ihh*^{+/-} thymus, the target cells will proliferate and differentiate faster. This would result in a larger DP population, thus a larger thymus in total (as observed on E16.5, Figure 3A-E). Once the size of the DP population increases 2-fold, *Ihh* concentrations will reach WT levels, and so the negative regulatory signal will be fully restored, resulting in a slowdown of proliferation and differentiation. As a consequence, DP production would be reduced, which would then reduce *Ihh* signal, and the homeostatic cycle would begin again, leading to increased variation in thymocyte number in the heterozygotes.

This model would therefore predict that, on E17.5, the upper limit of size in the *Ihh*^{+/-} thymus would be greater than in the WT and also that size would be more varied. To test this, we investigated thymocyte differentiation and proliferation on E17.5. As predicted, the *Ihh*^{+/-} thymi were on average larger,

the upper limits of thymus growth were increased 2-fold, and thymocyte number was much more variable ($P < .001$) than in the WT thymi (Figure 4D,E). The proportion of DP cells in the heterozygote thymus also mirrored the increased thymocyte number, with larger thymi containing more DP thymocytes (Figure 4D).


Because these data were consistent with concentration-dependent negative feedback on DP cell production, we assessed cell-cycle status of the target cell population of Ihh's negative regulatory action (CD25⁺ DN thymocytes, Figure 4A), from E17.5 Ihh^{+/-} thymi, grouped according to size. PI staining was carried out on purified CD25⁺ DN thymocytes from E17.5 Ihh^{+/-}, from 3 groups: I (thymus size > 1.3 relative to WT), II (thymus size 0.9-1.1 relative to WT), and III (thymus size < 0.9 relative to WT) (Figure 4F). In the larger Ihh^{+/-} thymi (I), consistent with Ihh concentration being equivalent to that in WT, the percentage of cells in cycle in the CD25⁺ DN population was the same as that found in WT littermates. In contrast, in the smaller Ihh^{+/-} thymi (III), where Ihh concentrations are lower than WT levels, the percentage of cells in cycle in the CD25⁺ DN population was higher. These data are consistent with the overall concentration of Ihh protein in the thymus influencing proliferation of the CD25⁺ DN cell, and with negative feedback restricting thymocyte number by restricting proliferation of an earlier target progenitor cell.

Analysis of E17.5 Ihh^{-/-} thymi revealed partial recovery of thymocyte number and the DP population (Figure 4D,E), compatible with the positive regulatory function of Ihh being required early, before pre-TCR signal transduction.

Distinct and redundant functions for Ihh and Shh on E16.5

To assess redundancy and overlapping functions of Ihh and Shh on the production of DP cells, we studied the effect of removal of one copy of *Ihh* from the E16.5 Shh^{-/-} thymus and vice versa. Removal of one copy of *Ihh* from Shh^{-/-} (Shh^{-/-}Ihh^{+/-}) increased cell number 3-fold relative to Shh^{-/-} littermate thymi (Figure 5A), indicating that the negative regulatory function of Ihh (revealed by reducing Ihh concentration) acts on a later stage of T-cell development than the positive Shh signal, so that reduction of Ihh signal allowed partial recovery of thymocyte number in the Shh^{-/-} thymus. In the Shh^{+/-}Ihh^{+/-} thymus, thymocyte number was not greater than in the

$Shh^{+/+}Ihh^{+/-}$ but was increased relative to WT, and there was greater variability. As shown previously,⁵ the proportion of DP cells was reduced in $Ihh^{-/-}$ and in $Shh^{-/-}$ thymi, and there was an increase in the proportion of DN cells (Figures 3()). Deletion of one copy of *Shh* in $Ihh^{-/-}$ thymi ($Shh^{+/-}Ihh^{-/-}$) caused a greater reduction in the proportion of DP cells than seen in $Ihh^{-/-}$ thymi, in all litters examined (Figure 5B,C). The proportion of DP cells was 3.6% in the $Shh^{+/-}Ihh^{-/-}$, compared with 19.7% in the $Shh^{+/-}Ihh^{+/+}$ and 12% in the $Shh^{+/-}Ihh^{-/-}$ littermate thymi (Figure 5C). Thus, both *Ihh* and *Shh* provide positive signals for DN cell expansion and differentiation, and it is the total amount of Hh signal that is critical at this stage.



The fact that the number of thymocytes was increased in the $Ihh^{+/-}Shh^{-/-}$ thymus compared with $Ihh^{+/+}Shh^{-/-}$ littermates allows a clear distinction to be made between the positive and negative regulatory roles for Hh signaling and indicates that *Ihh* concentration is important after *Shh* signaling, as rather than aggravating the phenotype, lowering the concentration of *Ihh* actually allowed partial recovery of DP thymocyte number.

Concentration-dependent regulation of thymocyte development by r-Hh treatment in FTOCs

To determine whether we could reconstitute the $Ihh^{-/-}$ and $Ihh^{+/-}$ thymus with exogenous Hedgehog protein, we treated FTOCs with recombinant Hedgehog (r-Hh). Mammalian Hh proteins are autocatalytically processed to form an active N-terminal fragment, which is highly homologous between *Shh* and *Ihh* and between species.^{6,7} We therefore treated FTOCs with recombinant mouse *Shh* N-terminus (r-mShh-N). We have previously shown that high-dose treatment of FTOCs with octylated recombinant human *Shh* N-terminus (oct-r-hShh-N) arrested thymocyte development at the DN stage,^{5,10}

whereas treatment with low concentrations of this protein increased thymocyte production.⁵ We therefore titrated the r-mShh-N in WT FTOCs and measured DP cell production after 3 days ([Figure 5D](#)). The activity of the r-mShh-N was very similar in FTOCs to that of the oct-r-hShh-N we had used in previous studies, and at 1.5 $\mu\text{g}/\text{mL}$ r-mShh-N arrested thymocyte development at the DN stage, decreasing the number of DP cells 80-fold, whereas, at the lowest concentration we assayed (0.05 $\mu\text{g}/\text{mL}$), we saw a modest increase in the production of DP cells ([Figure 5D](#)).

We then asked whether treatment of $Ihh^{+/-}$ FTOCs with r-Hh could restore the negative regulatory effect of Ihh on thymocyte development. Because $Ihh^{+/-}$ thymi contain approximately twice the number of thymocytes as WT thymi on E16.5, we chose a concentration of r-Hh that decreased DP production approximately 2-fold in our titration ([Figure 5D](#)). In FTOCs, we treated E15 $Ihh^{+/-}$ thymus lobes for 3 days with 0.25 $\mu\text{g}/\text{mL}$ r-mShh-N and compared thymocyte development with that in the untreated lobe from the same thymus and to WT littermate thymus lobes. The untreated $Ihh^{+/-}$ FTOCs produced approximately 4 times more thymocytes than their WT counterparts, and this expansion was evident in DN, CD8ISP, and DP populations ([Figure 5E,F](#)). Treatment with 0.25 $\mu\text{g}/\text{mL}$ r-mShh-N restored the negative regulatory signal and inhibited thymocyte development to WT levels. A reduction was seen not only in the number of DP cells produced but also in the expansion of the DN population ([Figure 5E,F](#)).

We then asked whether we could restore the positive regulatory function of Ihh on thymocyte development by treatment of $Ihh^{-/-}$ FTOCs with r-Hh. Given that treatment of $Ihh^{+/-}$ FTOCs with 0.25 $\mu\text{g}/\text{mL}$ r-mShh-N restored the heterozygote thymus to WT thymocyte production, we reasoned simplistically that treatment of the $Ihh^{-/-}$ thymus with the same concentration of r-mShh-N should mirror the $Ihh^{+/-}$ thymus, in which Ihh protein concentrations are sufficient to provide the early positive regulatory signal for thymocyte development but not the later negative regulatory signal. We treated $Ihh^{-/-}$ and littermate FTOCs with 0.25 $\mu\text{g}/\text{mL}$ r-mShh-N and compared thymocyte development in the treated thymus lobes with that in the untreated lobe from the same thymus. As seen previously ([Figure 5D-F](#)), r-mShh-N inhibited thymocyte development in the littermate FTOCs, but as predicted by our model, the treatment promoted thymocyte development in the $Ihh^{-/-}$ with increases in DN, ISP, and DP production ([Figure 5G](#)). Thus,

treatment with r-Hh had opposing outcomes on $Ihh^{-/-}$ and $Ihh^{+/-}$ FTOCs, and we demonstrated both the positive and negative regulatory functions of Ihh in vitro.

Ihh signaling in the adult heterozygote thymus

To determine whether Ihh is important in the adult thymus, we confirmed *Ihh* expression in sorted adult thymocyte populations by quantitative RT-PCR. We detected *Ihh* transcription in all thymocyte populations, with a 6-fold up-regulation between the DN3 and DP populations ([Figure 6A](#)). Given that the DP population makes up more than 80% of adult thymocytes and expresses more *Ihh* than other thymocyte populations or the stroma, it produces most of the Ihh protein in the thymus. We also assessed *Gli1* expression in sorted adult populations, and as reported previously,^{21,22} the pattern of *Gli1* transcription in adult thymocytes was similar to that in fetal thymocytes, with expression peaking in the CD25⁺ (DN2/DN3) DN cells and virtually undetectable in the DP population ([Figure 6B](#)), indicating that adult DP cells, although the major producers of Ihh, are not themselves responding to an Hh signal.^{10,21}




Figure 6

Thymocyte Ihh expression is required for adult thymocyte development.

(A,B) Expression of Ihh (A) and Gli1 (B) was assessed by quantitative RT-PCR in FACS-sorted populations of adult and fetal murine tissue. Levels of *Ihh* and *Gli1* transcription were normalized ([more ...](#))

To determine whether Ihh is also a negative regulator of adult thymus homeostasis, we compared the thymus of adult inbred $Ihh^{+/-}$ and WT littermates. As seen in the fetal heterozygote thymus ([Figures 3](#)), the upper limit to $Ihh^{+/-}$ thymocyte number was approximately 2-fold greater than in the WT littermates ([Figure 6C](#)), there was more variation between individual thymi, and *Ihh* transcription in $Ihh^{+/-}$ DP cells was one-half that in $Ihh^{+/+}$ DP cells ([Figure 6D](#)), consistent with negative feedback of Ihh from the DP population on their DN progenitors.

Ihh signaling in the adult Ihh conditional knockout thymus


To further study the role of Ihh produced by the thymocytes, rather than the

epithelium, on T-cell development in the adult thymus, we used 2 different conditional (“floxed”) *Ihh* mouse models.¹⁵ Excision was mediated by transgenic Cre in either the *vav* or CD2 transgenic cassettes.²⁷ The *vav* cassette drives Cre expression in all hematopoietic cells, including thymocytes at all stages of their development, but not thymic epithelium. The CD2 transgenic cassette drives Cre expression in lymphocytes only, with partial expression in thymocytes starting at the DN2 stage and complete expression in all thymocytes only from the DN4 stage onward.²⁷

In the case of the *vavCre* model, we confirmed efficient excision of the floxed *Ihh* allele by PCR amplification of the *Ihh* gene from thymocyte DNA from *vavCre*⁻ *Ihhfl/fl* and *vavCre*⁺ *Ihhfl/fl* littermates (Figure 6E). We compared mice either in which both *Ihh* alleles were floxed and excised by *vavCre* expression (*vavCre*⁺*Ihhfl/fl*) or in which one allele was null and the other floxed and excised (*vavCre*⁺*Ihhfl*⁻) and found a significant reduction in thymocyte number in both cases (Figure 6F,G). To demonstrate functionally that *Ihh* produced by thymocytes can mediate the early positive signal for differentiation, we assessed the DN populations in *vavCre*⁻*Ihhfl/fl* (littermate) and *vavCre*⁺*Ihhfl/fl* littermates (in which both alleles of *Ihh* are present in the thymus epithelium). In the *vavCre*⁺*Ihhfl/fl* thymus where Cre expression is complete at the DN1 stage,²⁷ there was a significant reduction in the DN4 population (from 39.4% to 20.1%) and a concomitant increase in the proportion of DN3 cells (from 41.4% to 57.7%) (Figure 6H,I). As seen in the fetal *Ihh*^{-/-} thymus, a slightly higher proportion of the DN3 population expressed icTCR-β than in the corresponding littermate DN3 population (Figure 6J,K), indicating that TCR-β locus rearrangement was not limiting DP cell production.

For the CD2Cre model, we confirmed efficient excision of the floxed *Ihh* allele by PCR amplification of the *Ihh* gene from thymocyte DNA from CD2Cre⁻*Ihhfl/fl* and CD2Cre⁺*Ihhfl/fl* littermates (Figure 7A). Analysis of the CD2Cre⁺*Ihhfl/fl* mice showed that, on average, thymi were larger and the upper limit of thymocyte number was increased relative to littermates (Figure 7B), indicating loss of negative regulation. However, there was no significant difference in the proportion of DN3 and DN4 cells (Figure 7C,D), indicating that the earlier positive signal was not affected. Thus, in the CD2Cre⁺*Ihhfl/fl* mice, where excision of *Ihh* happens at a later developmental stage than in the *vavCre*⁺*Ihhfl/fl* mice, *Ihh*'s positive regulatory role before pre-TCR

signaling remains intact, whereas its later negative regulatory role is compromised. The fact that, in contrast to the $vavCre^+Ihhfl/fl$ mice, DN populations were not affected in the $CD2Cre^+Ihhfl/fl$ is consistent with the later excision described in the $CD2Cre$ model²⁷ and indicates that *Ihh* production by the early DN populations provides an autocrine signal. Both conditional knockout models therefore demonstrate the functional importance of *Ihh* secreted by the thymocytes themselves. In both cases, some *Ihh* will still be produced by the thymic epithelium, but this is insufficient to provide either the full early positive signals or subsequent negative regulatory signals that control thymus homeostasis, hence the phenotypes observed.



Discussion

Here we show that the secreted signaling molecule *Ihh* regulates T-cell development, influencing thymus homeostasis and thymocyte number in both adult and fetus. Mice mutant in genes encoding several other secreted signaling molecules have reduced thymocyte numbers,^{4,5} but the phenotype of *Ihh* mutant mice is unusual in that, although thymocyte number and the transition to DP cell were reduced in the $Ihh^{-/-}$ thymus, they were actually increased in the $Ihh^{+/-}$ thymus, suggesting a novel role for *Ihh* in thymocyte homeostasis.

Analysis of both heterozygote and conditional *Ihh* knockout models showed that expression of *Ihh* by thymocytes is required to restrict the size of the thymus by transmitting negative signals to limit thymocyte number, and in vitro treatment of $Ihh^{+/-}$ FTOC with r-Hh protein restored this negative regulatory function.

The fact that *Ihh* was most highly expressed by the DP population that have down-regulated both *Gli1* and *Smo* transcription^{10,21,22} and are not Hh-

responsive¹⁰ suggests that *Ihh* regulates thymus homeostasis by providing a negative feedback loop on the production of DP cells ([Figure 7C](#)). Analysis of proliferation of the different thymocyte subsets indicated that this feedback targets the DN3 population. In addition, analysis of *vavCre⁺Ihhfl/fl* and *CD2Cre⁺Ihhfl/fl* thymi, and of *Ihh^{+/-}Rag^{-/-}* FTOCs showed that *Ihh* provides a positive signal for differentiation before pre-TCR signal transduction and a negative signal after pre-TCR signal transduction. Hh signaling is necessary for efficient generation of DP cells, as evidenced by the reduction in DP cells in the *Shh^{-/-}*, *Ihh^{-/-}*, and *Ihh^{-/-}Shh^{+/-}* thymi and by the increase in DP production in vitro by treatment of *Ihh^{-/-}* FTOCs with exogenous r-Hh. Both *Shh* made by the thymus epithelium^{5,10,20} and *Ihh* made by thymocytes and epithelium promote early thymocyte differentiation before pre-TCR signal transduction. However, as the production of DP and SP cells increases (both of which express higher levels of *Ihh* than their DN progenitors), so would the concentration of *Ihh*, which could then, having reached a critical threshold, provide negative feedback on the DN population, preventing the thymus growing ad infinitum. In the *Ihh^{+/-}* thymus, the concentration of *Ihh* produced would be one-half of the physiologic level produced in the WT thymus, allowing the thymus to grow approximately 2 times larger, before becoming subject to the “normal” (WT) levels of negative regulatory feedback. Analysis of the E16.5 fetal thymus facilitated detection of this negative feedback, as the first wave of production of DP thymocytes is synchronized.

Studies of conditional *Smo* knockout thymi showed that Hh pathway activation in thymocytes is essential for their survival, proliferation, and differentiation at the transition from DN1 to DN2.²¹ Our analysis of double mutants indicated that, although *Shh* secreted by the epithelium is dominant in providing this signal, *Ihh*, produced by thymocytes and stroma, has a redundant function to promote differentiation at the transition from DN1 to DN2. In addition, the double-mutant analysis on E16.5 enabled a clear distinction between the positive and negative regulatory functions to be made, as removal of one copy of *Ihh* from the *Shh^{-/-}* alleviated, rather than aggravated, the *Shh^{-/-}* phenotype and increased the production of DP cells, indicating that the negative regulatory action of *Ihh* is at a later developmental stage than the positive function of *Shh*. These different requirements for *Shh* and *Ihh* may also be the result of differences in concentrations of the 2 proteins. They are also probably the result of the

different spatial and temporal expression patterns of Shh and Ihh,^{10,20} and are consistent with Ihh being expressed most highly by DP cells, after Shh is required.

The phenotype of the *Ihh*^{+/-} and *Ihh*^{-/-} mice provides an explanation for an apparent discrepancy between data obtained from in vitro experiments¹⁰ and from the ex vivo analysis of *Shh*^{-/-5} and conditional *Smo* knockout thymi.²¹ In FTOCs, partial removal of endogenous Hh activity by treatment with neutralizing anti-Hh antibody (which can bind both Shh and Ihh) increased differentiation from DN to DP cell.¹⁰ Likewise, the development of human CD34⁺ thymocyte progenitors in vitro was accelerated by neutralization of Hh signaling.²⁴ These observations seemed to conflict with the phenotype of the *Shh*^{-/-} thymus, which showed reduced differentiation from DN to DP cell.⁵ Our analysis of *Ihh* mutant embryos demonstrates that in vivo T-cell development is regulated by the overall concentration of Hh protein that the developing thymocyte receives and that, in WT thyme, *Ihh* protein can actually function as a brake on DP cell production (explaining the impact of the reduction in Hh signaling by treatment with neutralizing anti-Hh antibody in WT FTOCs). Clearly, the concentration of *Ihh* protein that a given thymocyte receives will depend on the architecture of the thymus and the position of that cell in the thymus, relative to *Ihh*-producing cells.

Conditional deletion of *Smo* from T-lineage cells, using transgenic *Cre* under the control of the *lck* promoter,²¹ did not show an influence of Hh signaling on T-cell development after the DN2 stage, whereas the data presented here demonstrate that *Ihh* regulates the rate of differentiation from DN3 to DP cell. It would not be possible to detect the negative regulatory function of *Ihh* on the DN to DP transition in the conditional *Smo* knockout, as the *Smo*-deficient DN3 population would be unable to transduce any *Ihh* signal. Consistent with our model, in which *Ihh* production by DP cells feeds back to signal to the DN population, deletion of *Smo* using transgenic *Cre* controlled by the *CD4* promoter had no effect on T-cell development, confirming that the DP cells are not themselves responding to the *Ihh* they secrete.²¹

The fact that Hh pathway activation in thymocytes increases differentiation and expansion at the earliest stages of their development but reduces differentiation and proliferation at later developmental stages might seem surprising but has parallels in the development of other tissues, such as gut

and retina.^{32,33} For example, in retinal development, Hh signaling has different effects at different stages of development and has been shown to push precursor cells out of the cell cycle, to signal for differentiation at a distinct stage, and can also promote proliferation.^{32,34–36} A cell's interpretation of the Hh signal will depend on many factors, including strength and duration of signal and the external and intracellular context of signal transduction,^{7,16,37} and so Hh signaling may affect stem, progenitor, and mature cells differently and have opposing effects on cellular processes, depending on the state of differentiation of the cell.

In the future, it will be important to identify the molecular mechanisms and transcriptional targets that account for the positive and negative regulatory functions of Hh signaling on thymocyte development. Both cell-cycle inhibitors, such as *cdkn1* and *cdkn2* family molecules, and factors required for cell-cycle progression, such as cyclin D2, are Hh target genes in other cell types.^{32,36,38,39} It is therefore possible that cell-cycle inhibitors are transcriptional targets of the Hh pathway accounting for the negative regulatory function, whereas cyclin D2 is an Hh target in the DN2 population, accounting for the earlier positive regulatory function. The Hedgehog signaling pathway interacts with bone morphogenetic protein (BMP) and Wnt signaling pathways in the development of other tissues.^{19,40} BMP 2/4 signaling has previously been shown to negatively regulate thymocyte development,^{41–43} but Wnt signaling promotes thymocyte development.⁴ It is therefore possible that the opposing positive and negative functions of Ihh in thymocyte development are mediated in part by Wnt and BMP 2/4 signaling, respectively.

In conclusion, we show that Ihh produced by thymocytes promotes T-cell development before pre-TCR signal transduction and limits T-cell development after pre-TCR signal transduction in a concentration-dependent manner, thereby restricting thymocyte production and thymus size.

Acknowledgments

The authors thank Derek Davies (Cancer Research UK, London, United Kingdom) for cell sorting.

This work was supported by The Wellcome Trust, Medical Research Council,

Biotechnology and Biological Sciences Research Council, and Leukemia Research Fund. N.J.R. was supported by a Foulkes Foundation Fellowship.

Footnotes

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

Authorship

Contribution: S.V.O., A.L.H.-T., D.K.S., and T.C. prepared the manuscript and carried out experiments; and N.J.R., E.D., S.E.R., B.L., and J.T.D. contributed experimentally.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Tessa Crompton, Immunobiology Unit, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom; e-mail: t.crompton@ich.ucl.ac.uk .

References

1. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. *Proc Natl Acad Sci U S A*. 1995;92:377–381. [[PubMed](#)]
2. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. *Immunity*. 1999;10:547–558. [[PubMed](#)]
3. Maillard I, Fang T, Pear WS. Regulation of lymphoid development, differentiation, and function by the Notch pathway. *Annu Rev Immunol*. 2005;23:945–974. [[PubMed](#)]
4. Staal FJ, Clevers HC. Wnt signaling in the thymus. *Curr Opin Immunol*. 2003;15:204–208. [[PubMed](#)]
5. Shah DK, Hager-Theodorides AL, Outram SV, Ross SE, Varas A, Crompton T. Reduced thymocyte development in sonic hedgehog knockout embryos. *J Immunol*. 2004;172:2296–2306. [[PubMed](#)]
6. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev*. 2001;15:3059–3087. [[PubMed](#)]

7. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. *Nat Rev Genet.* 2006;7:841–850. [[PubMed](#)]
8. Varas A, Hernandez-Lopez C, Valencia J, et al. Survival and function of human thymic dendritic cells are dependent on autocrine Hedgehog signaling. *J Leukoc Biol.* 2008;83:1476–1483. [[PubMed](#)]
9. Uhmann A, Dittmann K, Nitzki F, et al. The Hedgehog receptor Patched controls lymphoid lineage commitment. *Blood.* 2007;110:1814–1823. [[PubMed](#)]
10. Outram SV, Varas A, Pepicelli CV, Crompton T. Hedgehog signaling regulates differentiation from double-negative to double-positive thymocyte. *Immunity.* 2000;13:187–197. [[PubMed](#)]
11. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. *Nat Immunol.* 2001;2:172–180. [[PubMed](#)]
12. Chiang C, Litingtung Y, Lee E, et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. *Nature.* 1996;383:407–413. [[PubMed](#)]
13. St-Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev.* 1999;13:2072–2086. [[PubMed](#)]
14. Zhang XM, Ramalho-Santos M, McMahon AP. Smoothed mutants reveal redundant roles for Shh and Ihh signaling including regulation of L/R symmetry by the mouse node. *Cell.* 2001;106:781–792. [[PubMed](#)]
15. Razzaque MS, Soegiarto DW, Chang D, Long F, Lanske B. Conditional deletion of Indian hedgehog from collagen type 2alpha1-expressing cells results in abnormal endochondral bone formation. *J Pathol.* 2005;207:453–461. [[PubMed](#)]
16. Ashe HL, Briscoe J. The interpretation of morphogen gradients. *Development.* 2006;133:385–394. [[PubMed](#)]
17. Borowski C, Martin C, Gounari F, et al. On the brink of becoming a T cell. *Curr Opin Immunol.* 2002;14:200–206. [[PubMed](#)]
18. Petrie HT, Tourigny M, Burtrum DB, Livak F. Precursor thymocyte proliferation and differentiation are controlled by signals unrelated to the pre-TCR. *J Immunol.* 2000;165:3094–3098. [[PubMed](#)]
19. Crompton T, Outram SV, Hager-Theodorides AL. Sonic hedgehog signalling in T-cell development and activation. *Nat Rev Immunol.* 2007;7:726–735. [[PubMed](#)]
20. Sacedon R, Varas A, Hernandez-Lopez C, et al. Expression of hedgehog proteins in the human thymus. *J Histochem Cytochem.* 2003;51:1557–1566. [[PubMed](#)]
21. Andaloussi AE, Graves S, Meng F, Mandal M, Mashayekhi M, Aifantis I. Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus. *Nat Immunol.*

2006;7:418–426. [[PubMed](#)]

22. Rowbotham NJ, Hager-Theodorides AL, Cebecauer M, et al. Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation. *Blood*. 2007;109:3757–3766. [[PubMed](#)]

23. Hager-Theodorides AL, Dessens JT, Outram SV, Crompton T. The transcription factor Gli3 regulates differentiation of fetal CD4⁻ CD8⁻ double-negative thymocytes. *Blood*. 2005;106:1296–1304. [[PubMed](#)]

24. Gutierrez-Frias C, Sacedon R, Hernandez-Lopez C, et al. Sonic hedgehog regulates early human thymocyte differentiation by counteracting the IL-7-induced development of CD34⁺ precursor cells. *J Immunol*. 2004;173:5046–5053. [[PubMed](#)]

25. Rowbotham NJ, Furmanski AL, Hager-Theodorides AL, et al. Repression of hedgehog signal transduction in T-lineage cells increases TCR-induced activation and proliferation. *Cell Cycle*. 2008;7:904–908. [[PubMed](#)]

26. Rowbotham NJ, Hager-Theodorides AL, Furmanski AL, Crompton T. A novel role for Hedgehog in T-cell receptor signaling: implications for development and immunity. *Cell Cycle*. 2007;6:2138–2142. [[PubMed](#)]

27. de Boer J, Williams A, Skavdis G, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. *Eur J Immunol*. 2003;33:314–325. [[PubMed](#)]

28. Hager-Theodorides AL, Rowbotham NJ, Outram SV, Dessens JT, Crompton T. Beta-selection: abundance of TCRbeta⁻/gammadelta⁻ CD44⁻ CD25⁻ (DN4) cells in the foetal thymus. *Eur J Immunol*. 2007;37:487–500. [[PubMed](#)]

29. Gounari F, Chang R, Cowan J, et al. Loss of adenomatous polyposis coli gene function disrupts thymic development. *Nat Immunol*. 2005;6:800–809. [[PubMed](#)]

30. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. *Development*. 2002;129:4753–4761. [[PubMed](#)]

31. Hoffman ES, Passoni L, Crompton T, et al. Productive T-cell receptor beta-chain gene rearrangement: coincident regulation of cell cycle and clonality during development in vivo. *Genes Dev*. 1996;10:948–962. [[PubMed](#)]

32. Neumann CJ. Hedgehogs as negative regulators of the cell cycle. *Cell Cycle*. 2005;4:1139–1140. [[PubMed](#)]

33. van den Brink GR. Hedgehog signaling in development and homeostasis of the gastrointestinal tract. *Physiol Rev*. 2007;87:1343–1375. [[PubMed](#)]

34. Locker M, Agathocleous M, Amato MA, Parain K, Harris WA, Perron M. Hedgehog signaling and the retina: insights into the mechanisms controlling the proliferative properties of neural precursors. *Genes Dev*. 2006;20:3036–3048. [[PubMed](#)]

35. Masai I, Yamaguchi M, Tonou-Fujimori N, Komori A, Okamoto H. The hedgehog-PKA pathway regulates two distinct steps of the differentiation of retinal ganglion cells: the cell-cycle exit of retinoblasts and their neuronal maturation. *Development*. 2005;132:1539–1553. [[PubMed](#)]
36. Agathocleous M, Locker M, Harris WA, Perron M. A general role of hedgehog in the regulation of proliferation. *Cell Cycle*. 2007;6:156–159. [[PubMed](#)]
37. Tenzen T, Allen BL, Cole F, Kang JS, Krauss RS, McMahon AP. The cell surface membrane proteins Cdo and Boc are components and targets of the Hedgehog signaling pathway and feedback network in mice. *Dev Cell*. 2006;10:647–656. [[PubMed](#)]
38. Yoon JW, Kita Y, Frank DJ, et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. *J Biol Chem*. 2002;277:5548–5555. [[PubMed](#)]
39. Shkumatava A, Neumann CJ. Shh directs cell-cycle exit by activating p57Kip2 in the zebrafish retina. *EMBO Rep*. 2005;6:563–569. [[PubMed](#)]
40. Varas A, Hager-Theodorides AL, Sacedon R, Vicente A, Zapata AG, Crompton T. The role of morphogens in T-cell development. *Trends Immunol*. 2003;24:197–206. [[PubMed](#)]
41. Cejalvo T, Sacedon R, Hernandez-Lopez C, et al. Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. *Immunology*. 2007;121:94–104. [[PubMed](#)]
42. Hager-Theodorides AL, Outram SV, Shah DK, et al. Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. *J Immunol*. 2002;169:5496–5504. [[PubMed](#)]
43. Graf D, Nethisinghe S, Palmer DB, Fisher AG, Merkschlager M. The developmentally regulated expression of Twisted gastrulation reveals a role for bone morphogenetic proteins in the control of T cell development. *J Exp Med*. 2002;196:163–171. [[PubMed](#)]

Articles from *Blood* are provided here courtesy of
American Society of Hematology